Abstract
The contemporary treatment of anal cancer is combined-modality therapy with radiation therapy, fluorouracil, and mitomycin. This therapy results in long-term disease-free survival and sphincter preservation in the majority of patients. Tempering these positive results is the high rate of treatment-related morbidity associated with chemoradiation therapy for anal cancer. The use of intensity-modulated radiation therapy (IMRT) has the potential to reduce acute and chronic treatment-related toxicity, minimize treatment breaks, and potentially improve disease-related outcomes by permitting radiation dose escalation in selected cases.
Original language | English (US) |
---|---|
Pages (from-to) | 1082-1089 |
Number of pages | 8 |
Journal | Oncology (Williston Park, N.Y.) |
Volume | 23 |
Issue number | 12 |
State | Published - Nov 15 2009 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research